Minapharm Pharmaceuticals results, Q3 2024
Net profit, assets, equity and cash flow for Q3 2024, against the same period a year earlier, from the published financial statements.
Net profit63.19 millionEGP · +1059.5% vs the same period a year earlier
Total assets11.83 billionEGP · +47.7% vs the same period a year earlier
Shareholders' equity4.45 billionEGP · +31.2% vs the same period a year earlier
Operating cash flow-76.01 millionEGP · −1590.0% vs the same period a year earlier
In short
- Minapharm Pharmaceuticals's net profit for Q3 2024 was about 63.19 million EGP, up +1059.5% from 5.45 million EGP in Q3 2023.
- Total assets at the end of Q3 2024 were about 11.83 billion EGP, and shareholders' equity about 4.45 billion EGP.
- Operating cash flow for Q3 2024 was negative at 76.01 million EGP.
Key lines against the same period a year earlier
This periodQ3 2023Change
Net profit63.19 million5.45 million+1059.5%
Gross profit636 million385 million+64.9%
Total assets11.83 billion8.01 billion+47.7%
Total liabilities7.38 billion4.62 billion+59.9%
Shareholders' equity4.45 billion3.39 billion+31.2%
Total liabilities and equity11.83 billion8.01 billion+47.7%
Operating cash flow-76.01 million-4.5 million−1590.0%
Investing cash flow96.95 million-242 million+140.1%
Financing cash flow-262 million136 million−292.6%
Net change in cash-242 million-110 million−119.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy